Phaseline

Targets › CLEC4C

CLEC4C (C-type lectin domain family 4 member C): drug programs, companies and trials

2 programs from 2 companies in 4 trials: 2 Phase 3, 1 Phase 2, 1 Phase 1; Immunology; next expected readout Mar 2027.

Lectin-type cell surface receptor which may play a role in antigen capturing by dendritic cells. Specifically recognizes non-sialylated galactose-terminated biantennary glycans containing the trisaccharide epitope Gal(beta1-3/4)GlcNAc(beta1-2)Man. (UniProt, Q8WTT0)

Open in Phaseline: the race on CLEC4C, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BiogenLitifilimab (BIIB059)
C-type lectin domain family 4 member C inhibitor
CLEC4CPhase 3Lupus Erythematosus, Systemic; Subacute Cutaneous Lupus ErythematosusMar 2027
BiocadLitifilimab (BCD-256)
C-type lectin domain family 4 member C inhibitor
CLEC4CPhase 1Systemic Lupus Erthematosus–

Conditions

Lupus Erythematosus, Systemic (2) Subacute Cutaneous Lupus Erythematosus (1) Systemic Lupus Erthematosus (1)

Modalities

antibody (1), mixed (1)

Companies

Biogen (1) Biocad (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.